| Name | Title | Contact Details |
|---|
Tanner is the intermountain area's premier professional services firm. At Tanner, our personal approach guarantees that you will work closely and consistently with partners and with team members who understand your business and personal objectives.
Welcome to The IN Group! The IN Group (TIG) beautifully brings together the magic of the group individual brands, Investigo, InX, Definia, Caraffi, Sigma Labs & BioTalent enabling us to design truly bespoke solutions. Our mission is simple - to unlock the power of people. We know that conventional recruitment cant always solve todays talent challenges, so we decided to break with convention and offer you SO much more with TIG. Meet our brands - Investigo – we recruit the talent you need - InX – we find the best leaders - Definia – we deliver digital programmes - Caraffi – we offer talent advisory & talent solutions (EVP/CVP/MSP/RPO) - Sigma Labs - we offer outstanding graduates amplified with exceptional training in the world of Tech - BioTalent - we offer life sciences recruitment with the means to nurture change-makers Unashamedly human talent solutions At the IN Group, were unashamedly human, were encourage to be our true self and we love what we do. We think youll feel this through the people you meet, the solutions we design and the results youll enjoy. We believe that when people rally behind an ambitious vision and a brilliant culture, it lights up every corner of your organisation. We believe in people, so they make change for better. Wed love to tell you more so come and say hello@wearetig.com and well tell you all about it!
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.